Extensively drug-resistant Gram-negative bacterial bloodstream infection in hematological disease
Li Zhou,1,* Shanglong Feng,1,2,* Guangyu Sun,1 Baolin Tang,1 Xiaoyu Zhu,1 Kaidi Song,1 Xuhan Zhang,1 Huaiwei Lu,3 Huilan Liu,1 Zimin Sun,1 Changcheng Zheng1,2 1Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technolog...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-02-01
|
| Series: | Infection and Drug Resistance |
| Subjects: | |
| Online Access: | https://www.dovepress.com/extensively-drug-resistant-gram-negative-bacterial-bloodstream-infecti-peer-reviewed-article-IDR |
| _version_ | 1819100276591689728 |
|---|---|
| author | Zhou L Feng S Sun G Tang B Zhu X Song K Zhang X Lu H Liu H Sun Z Zheng C |
| author_facet | Zhou L Feng S Sun G Tang B Zhu X Song K Zhang X Lu H Liu H Sun Z Zheng C |
| author_sort | Zhou L |
| collection | DOAJ |
| description | Li Zhou,1,* Shanglong Feng,1,2,* Guangyu Sun,1 Baolin Tang,1 Xiaoyu Zhu,1 Kaidi Song,1 Xuhan Zhang,1 Huaiwei Lu,3 Huilan Liu,1 Zimin Sun,1 Changcheng Zheng1,2 1Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China; 2Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China; 3Department of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China *These authors contributed equally to this work Background: Extensively drug-resistant Gram-negative bacterial (XDR-GNB) bloodstream infection (BSI) is difficult to treat and is associated with a high mortality rate in patients with hematological diseases. The aim of this study is to investigate the predisposing risk factors and the efficacy of the antibiotic treatment in these patients, including exploration of efficacy and adverse effects of high-dose tigecycline. Methods: Between January 2013 and December 2017, 27 XDR-GNB BSI patients with hematological diseases were diagnosed and retrospectively reviewed in the current study. Results: Clinical response in patients with severe complications (such as severe neutropenia >10 days, grade III–IV acute graft-versus-host disease (aGVHD), and concurrent pneumonia) was significantly lower than in patients without or with only mild complications (P=0.033). The efficacy rate was 62.5% (10/16) in patients with tigecycline-based combination therapy regimen, 77.8% (7/9) with a high-dose tigecycline regimen, and 42.9% (3/7) with a standard-dose tigecycline regimen (P=0.36). The 30-day survival rates of patients undergoing high-dose or standard-dose tigecycline treatment were 66.7% (95% CI: 28.2–87.8) and 57.1% (95% CI: 17.2–83.7), respectively, (P=0.603). Patients with mild complications were associated with superior 30-day survival rates than patients with severe complications (93.8% vs 36.4%, P=0.001), >10 days of neutropenia (90.9% vs 33.3%, P=0.012), severe aGVHD (100% vs 40%, P=0.049), and concurrent pneumonia (84.6% vs 57.1%, P=0.048). Conclusion: Our study indicated that XDR-GNB BSI in patients of hematological diseases with severe complications, such as long duration of neutropenia (>10 days) and severe aGVHD were associated with poor clinical response and short survival. We first indicated that these patients undergoing high-dose tigecycline treatment had an improved clinical response and an increased 30-day survival rate compared with the standard-dose group, although the differences were not statistically significant. This might be due to more severe complicated patients enrolled in high-dose group and the limited number size in our study. Keywords: carbapenem resistant bacterial infection, bloodstream infection, high-dose tigecycline, hematological malignancies |
| first_indexed | 2024-12-22T01:00:12Z |
| format | Article |
| id | doaj.art-bb3b803cf27b4341aa3aa4589b33cecc |
| institution | Directory Open Access Journal |
| issn | 1178-6973 |
| language | English |
| last_indexed | 2024-12-22T01:00:12Z |
| publishDate | 2019-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Infection and Drug Resistance |
| spelling | doaj.art-bb3b803cf27b4341aa3aa4589b33cecc2022-12-21T18:44:13ZengDove Medical PressInfection and Drug Resistance1178-69732019-02-01Volume 1248149144321Extensively drug-resistant Gram-negative bacterial bloodstream infection in hematological diseaseZhou LFeng SSun GTang BZhu XSong KZhang XLu HLiu HSun ZZheng CLi Zhou,1,* Shanglong Feng,1,2,* Guangyu Sun,1 Baolin Tang,1 Xiaoyu Zhu,1 Kaidi Song,1 Xuhan Zhang,1 Huaiwei Lu,3 Huilan Liu,1 Zimin Sun,1 Changcheng Zheng1,2 1Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China; 2Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China; 3Department of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China *These authors contributed equally to this work Background: Extensively drug-resistant Gram-negative bacterial (XDR-GNB) bloodstream infection (BSI) is difficult to treat and is associated with a high mortality rate in patients with hematological diseases. The aim of this study is to investigate the predisposing risk factors and the efficacy of the antibiotic treatment in these patients, including exploration of efficacy and adverse effects of high-dose tigecycline. Methods: Between January 2013 and December 2017, 27 XDR-GNB BSI patients with hematological diseases were diagnosed and retrospectively reviewed in the current study. Results: Clinical response in patients with severe complications (such as severe neutropenia >10 days, grade III–IV acute graft-versus-host disease (aGVHD), and concurrent pneumonia) was significantly lower than in patients without or with only mild complications (P=0.033). The efficacy rate was 62.5% (10/16) in patients with tigecycline-based combination therapy regimen, 77.8% (7/9) with a high-dose tigecycline regimen, and 42.9% (3/7) with a standard-dose tigecycline regimen (P=0.36). The 30-day survival rates of patients undergoing high-dose or standard-dose tigecycline treatment were 66.7% (95% CI: 28.2–87.8) and 57.1% (95% CI: 17.2–83.7), respectively, (P=0.603). Patients with mild complications were associated with superior 30-day survival rates than patients with severe complications (93.8% vs 36.4%, P=0.001), >10 days of neutropenia (90.9% vs 33.3%, P=0.012), severe aGVHD (100% vs 40%, P=0.049), and concurrent pneumonia (84.6% vs 57.1%, P=0.048). Conclusion: Our study indicated that XDR-GNB BSI in patients of hematological diseases with severe complications, such as long duration of neutropenia (>10 days) and severe aGVHD were associated with poor clinical response and short survival. We first indicated that these patients undergoing high-dose tigecycline treatment had an improved clinical response and an increased 30-day survival rate compared with the standard-dose group, although the differences were not statistically significant. This might be due to more severe complicated patients enrolled in high-dose group and the limited number size in our study. Keywords: carbapenem resistant bacterial infection, bloodstream infection, high-dose tigecycline, hematological malignancieshttps://www.dovepress.com/extensively-drug-resistant-gram-negative-bacterial-bloodstream-infecti-peer-reviewed-article-IDRExtensively drug-resistant bacterialbloodstream infectionhigh-dose tigecyclinehematological disease. |
| spellingShingle | Zhou L Feng S Sun G Tang B Zhu X Song K Zhang X Lu H Liu H Sun Z Zheng C Extensively drug-resistant Gram-negative bacterial bloodstream infection in hematological disease Infection and Drug Resistance Extensively drug-resistant bacterial bloodstream infection high-dose tigecycline hematological disease. |
| title | Extensively drug-resistant Gram-negative bacterial bloodstream infection in hematological disease |
| title_full | Extensively drug-resistant Gram-negative bacterial bloodstream infection in hematological disease |
| title_fullStr | Extensively drug-resistant Gram-negative bacterial bloodstream infection in hematological disease |
| title_full_unstemmed | Extensively drug-resistant Gram-negative bacterial bloodstream infection in hematological disease |
| title_short | Extensively drug-resistant Gram-negative bacterial bloodstream infection in hematological disease |
| title_sort | extensively drug resistant gram negative bacterial bloodstream infection in hematological disease |
| topic | Extensively drug-resistant bacterial bloodstream infection high-dose tigecycline hematological disease. |
| url | https://www.dovepress.com/extensively-drug-resistant-gram-negative-bacterial-bloodstream-infecti-peer-reviewed-article-IDR |
| work_keys_str_mv | AT zhoul extensivelydrugresistantgramnegativebacterialbloodstreaminfectioninhematologicaldisease AT fengs extensivelydrugresistantgramnegativebacterialbloodstreaminfectioninhematologicaldisease AT sung extensivelydrugresistantgramnegativebacterialbloodstreaminfectioninhematologicaldisease AT tangb extensivelydrugresistantgramnegativebacterialbloodstreaminfectioninhematologicaldisease AT zhux extensivelydrugresistantgramnegativebacterialbloodstreaminfectioninhematologicaldisease AT songk extensivelydrugresistantgramnegativebacterialbloodstreaminfectioninhematologicaldisease AT zhangx extensivelydrugresistantgramnegativebacterialbloodstreaminfectioninhematologicaldisease AT luh extensivelydrugresistantgramnegativebacterialbloodstreaminfectioninhematologicaldisease AT liuh extensivelydrugresistantgramnegativebacterialbloodstreaminfectioninhematologicaldisease AT sunz extensivelydrugresistantgramnegativebacterialbloodstreaminfectioninhematologicaldisease AT zhengc extensivelydrugresistantgramnegativebacterialbloodstreaminfectioninhematologicaldisease |